These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15632466)

  • 1. [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Chatani Y
    Clin Calcium; 2005 Jan; 15(1):9-14. PubMed ID: 15632466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
    Miki T; Minamide T
    Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
    Fukunaga M
    Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
    Mori H; Tanaka M; Kayasuga R; Masuda T; Ochi Y; Yamada H; Kishikawa K; Ito M; Nakamura T
    Bone; 2008 Nov; 43(5):840-8. PubMed ID: 18718565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
    Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
    Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of minodronic acid hydrate for the treatment of osteoporosis.
    Tanishima S; Morio Y
    Clin Interv Aging; 2013; 8():185-9. PubMed ID: 23440003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
    Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
    Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
    Takata S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study.
    Tanaka S; Yoshida A; Kono S; Ito M
    J Orthop Sci; 2017 May; 22(3):536-541. PubMed ID: 28108224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minodronic acid ameliorates vertebral bone strength by increasing bone mineral density in 9-month treatment of ovariectomized cynomolgus monkeys.
    Tanaka M; Mori H; Kawabata K; Mashiba T
    Bone; 2016 Jul; 88():157-164. PubMed ID: 27155564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis.
    Ito M; Sone T; Fukunaga M
    J Bone Miner Metab; 2010 May; 28(3):334-41. PubMed ID: 19937358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
    Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
    Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
    Greenspan SL; Harris ST; Bone H; Miller PD; Orwoll ES; Watts NB; Rosen CJ
    Am Fam Physician; 2000 May; 61(9):2731-6. PubMed ID: 10821153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate.
    Tanaka M; Matsugaki A; Ishimoto T; Nakano T
    J Bone Miner Metab; 2016 Mar; 34(2):234-41. PubMed ID: 25837430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.